中国生物制药（01177）今日盘中大涨5.18%，引起市场广泛关注。
消息面上，中生引领（上海）私募投资基金于今日揭牌成立，中国生物制药作为首轮出资人之一参与其中。该基金目标总规模达10亿元，首轮规模为5亿元。除中国生物制药外，浦东创投集团、孚腾资本、杭州科百特也参与了首轮出资。基金将由浦东创投集团旗下浦东资本担任管理人。
中生引领基金的投资策略聚焦于成长期创新型生物医药企业，旨在赋能企业在研发、生产、销售等全流程环节。中国生物制药参与设立该基金，彰显了公司在生物医药创新领域的战略布局和长期发展眼光。这一举措有望为公司带来潜在的投资回报，并可能促进公司在生物医药领域的技术创新和市场拓展，从而推动公司的长期增长。投资者对此反应积极，推动公司股价显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.